New York Senate Bill S08678

New York 2025-2026 Regular Session

• Introduced: 1/7/26
• Refer: 1/7/26

Caption

Expands Medicaid coverage to include pharmacological treatment for hyperhidrosis when such treatment is ordered by a physician, registered physician assistant, or registered nurse practitioner; provides that the provisions shall not take effect unless all necessary approvals under federal law and regulation have been obtained to receive federal financial participation in the costs.

Summary

S08678 would amend New York’s Social Services Law to add pharmacological treatment for hyperhidrosis to the list of Medicaid-covered services. Hyperhidrosis is a condition involving excessive sweating, and the bill limits coverage to treatment ordered by a physician, registered physician assistant, or registered nurse practitioner. The bill also includes a federal conformity condition: the new Medicaid coverage would not take effect unless the necessary federal approvals are obtained so the state can receive federal financial participation for the covered services. The act is set to take effect on April 1, 2027.

Impact

If enacted, the bill would expand Medicaid benefits in New York by requiring coverage for prescription or other pharmacological treatment for hyperhidrosis under Social Services Law section 365-a. It would affect Medicaid recipients who suffer from the condition, as well as providers who prescribe or order treatment, while preserving existing licensure and scope-of-practice rules under the Education Law. The measure is contingent on federal approval, so its practical effect depends on compliance with federal Medicaid requirements.

Sentiment

No committee transcript or recorded vote information was provided, so there is no direct evidence of debate or formal support/opposition in the available materials. Based on the bill text and caption, the measure appears to be a targeted health-coverage expansion rather than a broad policy change, suggesting a generally narrow and technical policy purpose.

Contention

The main potential point of contention is cost and Medicaid coverage expansion, since the bill expressly conditions implementation on federal approval and federal financial participation. Another possible issue is whether hyperhidrosis treatment should be covered as a Medicaid benefit and whether the condition warrants inclusion alongside other medically necessary treatments. The bill also preserves existing scope-of-practice rules, which may reduce professional licensing concerns.